To influence policy on critical issues like the Priority Review Voucher, biotech CEOs are forming consortiums and going to Washington as a unified group. This collaborative approach is more effective than individual company efforts because it demonstrates a widespread industry problem that needs a legislative solution.

The current political and regulatory environment means running a biotech company is no longer just about science and capital. CEOs must now actively engage in policy discussions and lobby legislators to ensure the ecosystem remains favorable for innovation. Ignoring politics is no longer an option.

Senator Farry translates abstract policy into relatable human impact by sharing his wife's breast cancer survival story. He explains how decades of life sciences innovation made her otherwise "normal" treatment and cure possible. This personal narrative is a powerful tool to help colleagues understand the tangible, life-saving value of the industry's work.

Bio is creating a formal system for biotech companies to report challenges with the FDA. Bio will synthesize this feedback monthly and present it directly to FDA leadership, creating a novel channel to elevate systemic issues and improve accountability.

The Orphan Drug Act successfully incentivized R&D for rare diseases. A similar policy framework is needed for common, age-related diseases. Despite their massive potential markets, these indications suffer from extremely high failure rates and costs. A new incentive structure could de-risk development and align commercial goals with the enormous societal need for longevity.

Senator Frank Farry counters one-sided pitches by asking two key questions: "What's not so great about it?" and "Who's gonna be in my office tomorrow opposing this?" This forces a more honest, holistic discussion and reveals the full context of a legislative issue, preventing him from being misled by advocates.

Thriving life sciences ecosystems in Ireland, the UK, and Massachusetts did not grow by accident. Their success is the result of deliberate, long-term government strategies, including tax incentives, shared R&D infrastructure like the UK's 'Catapult' network, and fostering deep connections between technology, hospitals, and capital.

Senators from the purple state of Pennsylvania must build coalitions that cross party lines to win elections. This electoral necessity, unlike in safe red or blue states, forces them to find common ground and work together, as many of their constituents voted for politicians from both parties.

Effective patient advocacy in the Huntington's disease community involved more than raising awareness. Advocates achieved a regulatory reversal by directly engaging with lawmakers' offices, such as that of Senator Ron Johnson. This targeted political action was crucial in getting their concerns about the FDA's previous stance heard and ultimately changed.